Cargando…
Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
BACKGROUND: Androgen deprivation therapy is the mainstay of medical treatment for prostate cancer (Pca); however, it is associated with an increased risk of adverse cardiovascular (CV) events and death. To date, CV death has been the leading noncancer cause of death in Pca patients. Both GnRH antago...
Autores principales: | Gu, Li, Li, Xurui, Liu, Wentao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102515/ https://www.ncbi.nlm.nih.gov/pubmed/37065739 http://dx.doi.org/10.3389/fendo.2023.1157857 |
Ejemplares similares
-
Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding
por: Flanagan, Colleen A., et al.
Publicado: (2017) -
Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders
por: Merkison, Jamie, et al.
Publicado: (2022) -
Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023) -
Ovarian stimulation in IVF couples with severe male factor infertility: GnRH antagonist versus long GnRH agonist
por: Lv, Mu, et al.
Publicado: (2022) -
A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol
por: Li, Yubin, et al.
Publicado: (2021)